WLK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Westlake Corp (WLK) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. Despite positive analyst ratings and upward price target revisions, the company's recent financial performance is significantly weak, with substantial YoY declines in revenue, net income, EPS, and gross margin. Additionally, the technical indicators are mixed, and the options data suggests bearish sentiment in the short term. Given the lack of strong positive catalysts and the absence of proprietary trading signals, it is better to hold off on buying WLK for now.
The technical indicators present a mixed picture. The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is neutral at 61.366, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 106.935, and resistance is at 115.324. The stock has an 80% chance to decline by 0.86% in the next day and 1.1% in the next week, but a 13.93% chance to rise in the next month.
Analysts have raised price targets significantly, citing higher oil price assumptions, tightened chemical markets, and supply disruptions due to the Iran conflict. The company's Performance and Essential Materials (PEM) segment is expected to benefit from these dynamics.
The company's financial performance in Q4 2025 was extremely weak, with revenue down 10.90% YoY, net income down 7842.86% YoY, EPS down 8560.00% YoY, and gross margin down 79.81% YoY. Additionally, there is no recent positive news or significant insider/hedge fund activity to support the stock.
Westlake's Q4 2025 financials were poor, with revenue at $2.533 billion (-10.90% YoY), net income at -$542 million (-7842.86% YoY), EPS at -$4.23 (-8560.00% YoY), and gross margin at 2.13% (-79.81% YoY). These figures indicate significant challenges in profitability and growth.
Analysts are generally bullish on WLK, with multiple firms raising price targets recently. Truist raised the target to $127, UBS to $139, Citi to $130, and BMO Capital to $127, all maintaining Buy or Outperform ratings. The positive outlook is driven by higher oil price assumptions, tightened chemical markets, and supply disruptions due to geopolitical conflicts.
